Data on Advaxis’ Clinical Programs to be Presented at Upcoming Medical Meetings
ASCO - Genitourinary Cancers Symposium February 12-15, 2020, San Francisco, California |
Title: “KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel” Presenter: Dr. Mark N. Stein, Associate Professor, Division of Hematology/Oncology, Columbia University Medical Center Abstract: 126, Poster number F6 Date: Thursday, February 13, 2020 Time: 11:30AM – 1:00 PM, 5:30PM - 6:30 PM PT |
IASLC 2020 Targeted Therapies of Lung Cancer Meeting February 19-22, 2020, Santa Monica, California |
Session: Immunotherapy Combinations Title: A Phase 1 Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer Presenter: Dr. Jennifer Carlisle, Assistant Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University Date: Saturday, February 22, 2020 Time: 7:00 am PT |
Immuno-oncology 360° February 26-28, 2020, New York, New York |
Session: IO Novel Technologies Title: “Clinical Updates for Advaxis’ Pipeline of Lm-based Immunotherapies in Oncology” Presenter: Andres A. Gutierrez MD PhD – Advaxis’ Chief Medical Officer and Executive Vice President Date: Thursday, February 27, 2020 Time: 11:00 am ET |
About
To learn more about
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management, including but not limited to statements related to the expected clinical development of the Company’s drug product candidates. These and other risks are discussed in the Company’s filings with the
Contact:
212.915.2564
tim@lifesciadvisors.com
Source: Advaxis, Inc.